RBC Capital Sticks to Their Buy Rating for uniQure (QURE)
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Luca Issi reiterated a Buy rating on uniQure (QURE) with a $65 price target, noting the stock closed at $40.07. This follows a recent Buy from Barclays' Eliana Merle, while Goldman Sachs maintains a Hold rating. Issi covers the healthcare sector and has a 39.45% success rate on recommendations.
In a report released yesterday, Luca Issi from RBC Capital reiterated a Buy rating on uniQure, with a price target of $65.00. The company’s shares closed yesterday at $40.07.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Issi covers the Healthcare sector, focusing on stocks such as Argenx Se, Alnylam Pharma, and uniQure. According to TipRanks, Issi has an average return of -1.4% and a 39.45% success rate on recommended stocks.
In addition to RBC Capital, uniQure also received a Buy from Barclays’s Eliana Merle in a report issued today. However, on July 20, Goldman Sachs maintained a Hold rating on uniQure (NASDAQ: QURE).